Ivanka Trump’s photo with son sparks backlash over US policy to take away children of undocumented migrants

Washington, May 20: The United States recorded another 1,536 coronavirus deaths over the past 24 hours, the Johns Hopkins University tracker said.

That figure, tallied as of 8:30 pm (0030 GMT), raises to 91,845 the total number of COVID-19 deaths in the US.

The US tops the global rankings both for the highest death toll and the highest number of infections, with more than 1.5 million cases.

Tokyo, April 6: Japan Prime Minister Shinzo Abe is planning to declare a state of emergency in view of the surging cases of coronavirus in the country, especially in Tokyo and other large cities, government sources said on Monday.

Pressure had been mounting on Abe to make the declaration amid a spurt in COVID-19 cases recently, with calls for the move from Tokyo Governor Yuriko Koike and the Japan Medical Association intensifying, Xinhua news agency reported.

The Tokyo metropolitan government, along with healthcare specialists, said that the number of hospital beds available for coronavirus patients will soon reach capacity, with the health ministry rapidly trying to secure more beds.

Adding to pressure on the government to demonstrably bolster its preventive and countermeasures to the spread of the virus, a panel of government experts warned recently that the country's healthcare system could collapse if coronavirus cases continue to spike.

The healthcare system in Tokyo and four other prefectures are under increased strain and "drastic countermeasures need to be taken as quickly as possible," the experts said.

As of Sunday, 143 new cases of COVID-19 were recorded in Tokyo, a record daily high for the capital, bringing the total to 1,034, with Japan's health ministry and local governments adding that nationwide cases rose to 3,531 as of Sunday afternoon.

Beijing/Zurich, Mar 4: China has approved the use of Swiss drugmaker Roche's anti-inflammation drug Actemra for patients who develop severe complications from the coronavirus as it urgently hunts for new ways to combat the deadly infection that is spreading worldwide.

China is hoping that some older drugs could stop severe cytokine release syndrome (CRS), or cytokine storms, an overreaction of the immune system which is considered a major factor behind catastrophic organ failure and death in some coronavirus patients.

Actemra, a biologic drug approved in 2010 in the United States for rheumatoid arthritis (RA), inhibits high Interleukin 6 (IL-6) protein levels that drive some inflammatory diseases.

China's National Health Commission said in treatment guidelines published online on Wednesday that Actemra can now be used to treat coronavirus patients with serious lung damage and high IL-6 levels.

Separately, researchers in the country are testing Actemra, known generically as tocilizumab, in a clinical trial expected to include 188 coronavirus patients and running until May 10.

Roche, which donated 14 million yuan ($2.02 million) worth of Actemra during February, said the trial was initiated independently by a third party with the aim of exploring the efficacy and safety of the drug in coronavirus patients with CRS.

It added that there was currently no published clinical trial data on the drug's safety or efficacy against the virus.

More than 3,000 people have died and 93,000 have been infected by the novel coronavirus thought to have originated in Wuhan, China, before spreading to around 90 countries including the United States, Italy, Switzerland, France and Germany.

The Swiss company, for which China is its No. 2 market behind the United States, also makes diagnostic gear to detect the coronavirus.

Since Actemra's approval a decade ago, it has become a go-to drug against other inflammatory conditions, including cytokine storms in cancer patients receiving cell therapies from Novartis and Gilead Sciences.

In 2012 it helped save the life of a young U.S. girl, the first child to be treated for leukaemia with Novatis' Kymriah, from a post-treatment rush of IL-6.

Priced at between $20-30,000 annually for RA according to SSR Health, Roche's medicine is also used for rare juvenile arthritis and giant cell arteritis, or inflammation of the blood vessels.